Regeneron Disputes Claim It Didn’t Disclose Govt. Funding In Antibody Patent

By John Wilkerson / October 20, 2020 at 2:56 PM
Updated Story Regeneron disputes allegations it did not disclose that the U.S. government funded development of the company’s coronavirus antibody in its patent for REGN-COV2. If the allegations are true, the government could take ownership of the patent to control the drug’s price, according to Knowledge Ecology International Director James Love. Disclosing government funding in patents is required by a contract between Regeneron and the Biomedical Advanced Research and Development Authority, by the Bayh-Dole Act and by...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.